Applied DNA Sciences Inc., a Stony Brook, N.Y.-based provider of molecular technologies, including diagnostics, said it has received approximately $5.3 million in net proceeds calendar year to date as a result of the exercise of equity warrants. Applied DNA issued approximately 2.6 million warrants in connection with an underwritten public offering that closed on Nov. 15, 2019. Each warrant entitles its owner to purchase one share of common stock in the company at a per share price of $5.25 until Nov. 15, 2024. Approximately 1.5 million warrants associated with the Nov. 15, 2019 offering remain outstanding.
Palo Alto, Calif.-based Limbix Inc. raised a $9 million series A led by GSR Ventures. Also joining the financing round are other existing Limbix investors, including Sequoia Capital, Storm Ventures, Nextgen Venture Partners, and Bixink Therapeutics. The new funding enables further research and development of the company's Limbix Spark, the first prescription digital therapeutic designed to treat adolescents with depression.
Silk Road Medical Inc., a Sunnyvale, Calif.-based developer of a treatment for blockages in the carotid artery at risk of causing a stroke, reported the pricing of an underwritten public offering common stock at $39 per share. Of 6,808,154 shares in the offering, 1,923,076 shares are being offered for sale by Silk Road Medical, and the remaining shares are being offered for sale by certain selling securityholders. In addition, the selling securityholders have granted the underwriters a 30-day option to purchase up to an additional 1,021,223 shares of common stock at the public offering price, less the underwriting discounts and commissions. The gross proceeds from the offering to Silk Road are expected to be about $75 million. Silk Road Medical will not receive proceeds from the sale of its common stock by selling securityholders. The offering is expected to close May 8, 2020. Silk Road Medical intends to use the net proceeds from the offering to expand its sales force and operations, increase research and development activities, conduct or sponsor clinical studies and trials, lease new facilities, expand internationally, and to provide for working capital and other general corporate purposes. J.P. Morgan and BofA Securities are acting as joint book-running managers of the offering. Citigroup is also acting as book-running manager. Stifel is acting as co-manager.
Titan Medical Inc., of Toronto, closed its previously reported registered direct offering of 5,514,504 common shares of the company at a price of US$0.36268 per share and 2,757,252 unregistered common share purchase warrants, resulting in total gross proceeds to the company of approximately US$2 million. Each whole warrant is exercisable to purchase one common share at an exercise price of US$0.3002 per share for a period of 5.5. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. Titan intends to use the net proceeds from the offering for general corporate purposes including: resuming the development of its single-port robotic surgical system, instruments and accessories; funding working capital (including the reduction of outstanding payables); and capital expenditures.